Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice

被引:1
|
作者
Venanzi, F. M. [1 ]
Barucca, A. [1 ,2 ]
Havas, K. [1 ]
Capitani, M. [1 ]
Provinciali, M. [2 ]
Scotti, S. [2 ]
Concetti, A. [1 ]
机构
[1] Univ Camerino MC, Lab Translat Biol, Dept Biol MCA, Camerino, Italy
[2] INRCA Ancona, Lab Tumor Immunol, Sci Technol Area, Ancona, Italy
关键词
Breast cancer; Anti-HER-2; antibody; HER-2 DNA vaccination; Flt-3 ligand gene; TYROSINE KINASE RECEPTOR; DENDRITIC CELLS; IN-VIVO; BREAST-CANCER; LUNG-CANCER; RESPONSES; ANTIGEN; GENERATION; ADJUVANT; ANTIBODY;
D O I
10.1016/j.vaccine.2010.03.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fms-like tyrosine-kinase 3 ligand (Flt-3L), is a powerful hematopoyetic growth factor, known to modulate the immune response against delivered antigens by acting either as an adjuvant or tolerogenic stimulus. In this study we evaluated the use of murine Flt-3 ligand plasmid (pFI) in combination with a DNA vaccine encoding rat-p185 oncoprotein extra cellular domain (pECD) in the prevention of mammary carcinogenesis in rat-neu HER-2 mutated (neuT) transgenic mice. We demonstrate that intramuscular (i.m.) co-immunization of pFI inhibits the production of anti-HER-2 antibody elicited by pECD vaccine, resulting in the development of spontaneous carcinomas in all co-immunized mice. The inhibitory effect on antibody production by mFlt3 gene appeared to be: dose-dependent, linked to the injection site and timing, and transient in nature. Additionally, we show that co-administration of pFI and pECD plasmids was unable to trigger cytotoxic T-cell immune response in neuT mice. On the other hand, we found that the combination of pFI with pECD had no impact on the ability of pECD to reject HER-2+ transplantable tumors in parental mice. In summary our results demonstrate that, depending on tumor model, co-administration of pFI gene can produce untoward effects to immune response, and thus its application as a vaccine adjuvant should be carefully evaluated. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3841 / 3847
页数:7
相关论文
共 31 条
  • [1] Limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in Her-2/neu transgenic mice
    Lo Iacono, M
    Cavallo, F
    Quaglino, E
    Rolla, S
    Iezzi, M
    Pupa, SM
    De Giovanni, C
    Lollini, PL
    Musiani, P
    Forni, G
    Calogero, RA
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2005, 18 (02) : 351 - 363
  • [2] Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice
    Quaglino, E
    Iezzi, M
    Mastini, C
    Amici, A
    Pericle, F
    Di Carlo, E
    Pupa, SM
    De Giovanni, C
    Spadaro, M
    Curcio, C
    Lollini, PL
    Musiani, P
    Forni, G
    Cavallo, F
    CANCER RESEARCH, 2004, 64 (08) : 2858 - 2864
  • [3] The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression
    Baturin, DA
    Alimova, IN
    Anisimov, VN
    Popovich, IG
    Zabezhinski, MA
    Provinciali, M
    Mancini, R
    Franceschi, C
    NEUROENDOCRINOLOGY LETTERS, 2001, 22 (06) : 441 - 447
  • [4] Prevention by delay: Nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice
    Cavallo, F
    Di Carlo, E
    Quaglino, E
    Iezzi, M
    Strasly, M
    Bussolino, F
    Colombo, MR
    Nanni, R
    Lollini, PL
    Musiani, P
    Forni, G
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2001, 15 (04): : 351 - 358
  • [5] HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice
    Manjili, MH
    Wang, XY
    Chen, X
    Martin, T
    Repasky, EA
    Henderson, R
    Subjeck, JR
    JOURNAL OF IMMUNOLOGY, 2003, 171 (08): : 4054 - 4061
  • [6] Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a flt-3 ligand fusion vaccine
    Orlandi, Francesca
    Venanzi, Franco M.
    Concetti, Antonio
    Yamauchi, Hanako
    Tiwari, Shakuntala
    Norton, Larry
    Wolchok, Jedd D.
    Houghton, Alan N.
    Gregor, Polly D.
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6195 - 6203
  • [7] DNA immunization with a combination of rat neu antigen, CD86, and 4-1BB ligand results in the generation of HER-2/neu (HER-2) antibodies in neu transgenic mice
    Buonavista, N
    Shiota, FM
    Hellström, KE
    Hellström, I
    Disis, ML
    CANCER GENE THERAPY, 1998, 5 (06) : S2 - S2
  • [8] HER-2/NEU (HER2) peptide based vaccine with FLT3 ligand (FL) +/- GM-CSF as an adjuvant.
    Disis, ML
    Rinn, K
    Davis, D
    Caron, D
    Schiffman, K
    BLOOD, 2000, 96 (11) : 456A - 456A
  • [9] A combination of DNA and cell vaccines prevent the progression of preneoplastic lesions in HER-2/Neu transgenic mice as shown by gene expression and morphologic data
    Cavallo, F
    Rolla, S
    Quaglino, E
    Iezzi, M
    De Giovanni, C
    Lollini, PL
    Lanzardo, S
    Lo Iacono, M
    Crispi, S
    Deluca, P
    Calogero, RA
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1321S - 1322S
  • [10] Co-expression of human prolactin drastically reduces breast cancer incidence in HER2/neu transgenic mice
    Scotti, Michele L.
    Peirce, Susan K.
    Tomblyn, Seth
    Derrick, Blake
    Langenheim, John
    Jacquemart, Isabelle
    Park, Jang Pyo
    Chen, Wen
    CANCER RESEARCH, 2006, 66 (08)